SidE-Mediated Ubiquitination System for Specific Substrate Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeting ubiquitination in cancer and other pathologies often result in broad 'off-target' effects due to non-specificity, highlighting the need for more specific upstream regulators to modulate substrate ubiquitination.
Innovation Solution
A novel ubiquitination system independent of E1 and E2 enzymes, utilizing ADP-ribosylation mediated by members of the SidE effector family from Legionella pneumophila, which activates ubiquitin with β-nicotinamide adenine dinucleotide (β-NAD) and transfers an ADP from β-NAD to ubiquitin, enabling ATP-independent ubiquitination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional E1-E2-E3 ubiquitination system is used, then ubiquitination process can be carried out, but broad off-target effects occur due to non-specificity
Solution Approach 1:
The patent extracts and eliminates the E1 and E2 enzymes from the conventional ubiquitination system, retaining only the E3 ligase component. This extraction approach allows for specific targeting of substrates by individual E3 ligases without the broad non-specific activity inherent in the complete E1-E2-E3 system, thereby reducing off-target effects while maintaining ubiquitination functionality.
2Device complexity
If conventional ATP-dependent ubiquitination is used, then ubiquitination process proceeds, but energy consumption and complexity increase
Solution Approach 1:
The patent removes the ATP-dependent E1 activating enzyme and E2 conjugating enzyme from the system, retaining only the E3 ligase. This extraction simplifies the system by eliminating the energy-consuming activation and transfer steps, allowing direct substrate modification by the E3 ligase without ATP hydrolysis, thereby reducing both enzyme complexity and energy consumption.
3Reliability
If broad spectrum proteasome inhibition is used, then protein degradation is prevented, but side effects increase due to lack of specificity
Solution Approach 1:
The patent extracts the therapeutic target from the broad proteasome to the specific E3 ligase level. By focusing on individual E3 ligases that modify specific substrates involved in disease pathways, the system enables precise therapeutic intervention at the upstream regulatory level, avoiding the widespread effects of proteasome inhibition while maintaining disease-modifying capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for specific modulation of ubiquitination processes without the need for ATP, potentially reducing side effects and providing a more targeted therapeutic intervention by identifying and inhibiting specific substrates involved in disease pathways.
Implementation Method 1
utilizing ADP-ribosylation mediated by members of the SidE effector family from Legionella pneumophila, which activates ubiquitin with β-nicotinamide adenine dinucleotide (β-NAD) and transfers an ADP from β-NAD to ubiquitin
Data Source
AI summary
An unprecedented mechanism of ubiquitination that is independent of E1 and E2 enzymes, instead relying on activation of ubiquitin by ADP-ribosylation, and which is mediated by members of the SidE effector family encoded by the bacterial pathogen Legionella pneumophila is disclosed. The herein disclosed method demonstrates a method in which ubiquitination can be carried out by a single enzyme. In addition, the present disclosure also provides compositions that may be used in ubiquitination assays and/or methods of screening active substance that may inhibit the ubiquitination process.